Cell models of arrhythmogenic cardiomyopathy: advances and opportunities

Elena Sommariva1,*, Ilaria Stadiotti1,*, Gianluca L. Perrucci1,2, Claudio Tondo2,3 and Giulio Pompilio1,2

ABSTRACT
Arrhythmogenic cardiomyopathy is a rare genetic disease that is mostly inherited as an autosomal dominant trait. It is associated predominantly with mutations in desmosomal genes and is characterized by the replacement of the ventricular myocardium with fibrous fatty deposits, arrhythmias and a high risk of sudden death. In vitro studies have contributed to our understanding of the pathogenic mechanisms underlying this disease, including its genetic determinants, as well as its cellular, signaling and molecular defects. Here, we review what is currently known about the pathogenesis of arrhythmogenic cardiomyopathy and focus on the in vitro models that have advanced our understanding of the disease. Finally, we assess the potential of established and innovative cell platforms for elucidating unknown aspects of this disease, and for screening new potential therapeutic agents. This appraisal of in vitro models of arrhythmogenic cardiomyopathy highlights the discoveries made about this disease and the uses of these models for future basic and therapeutic research.

KEY WORDS: Arrhythmogenic cardiomyopathy, ACM, ARVC, Cell models, In vitro, Molecular mechanisms

Introduction
Arrhythmogenic cardiomyopathy (ACM) is a genetic disease associated with ventricular arrhythmias and a high risk of sudden cardiac death (see Box 1 for a glossary of terms). ACM affects mainly young individuals and trained athletes, and has a worldwide prevalence ranging from 1:1000 to 1:5000 (Basso et al., 2009). ACM is characterized by the substitution of the myocardium, the heart muscle, with fibro-fatty deposits, particularly within the free wall of the right ventricle (RV) (Fig. 1). This process exacerbates electric instability and causes impaired ventricular mechanical function, leading to arrhythmias and progressive heart failure (Box 1) (Marcus et al., 1982).

ACM is mostly inherited as an autosomal dominant trait and is characterized by incomplete penetrance and variable expressivity (Basso et al., 2009). Recessive forms and compound heterozygosis (Box 1) have also been reported (McKoy et al., 2000; Norgert et al., 2000; Soveizi et al., 2017; Xu et al., 2010). Despite genetic heterogeneity, the majority of genotyped ACM patients harbor mutations in genes that encode desmosomal proteins (Box 2), including plakoglobin (JUP), desmoplakin (DSP), plakophilin-2 (PKP2), desmoglein-2 (DSG2) and desmocollin-2 (DSC2) (Lazzarini et al., 2015). Mutations in non-desmosomal genes, including transforming growth factor-β3 (TGFB3), ryanodine receptor 2 (RYR2), transmembrane protein 43 (TMEM43), lamin A/C (LMNA), desmin (DES), titin (TTN), phospholamban (PLN) and αT-catenin (CTNNA3), are also proposed to associate with ACM (Lazzarini et al., 2015), although phenotypical overlap with other cardiomyopathies cannot be excluded.

In the clinic, ACM presents a wide phenotypic spectrum (Box 3). Despite having genetic bases, ACM is not a congenital disease; clinical manifestations often develop between the second and fourth decade of life (Nava et al., 2000). Moreover, despite the autosomal inheritance, more males are clinically affected than are females (Corrado and Thiene, 2006; Bauce et al., 2008). Indeed, males show earlier arrhythmia manifestation (Blonsale et al., 2013) and more severe disease expression (Bauce et al., 2008; Marcus et al., 2007, 1982; Blomstrom-Lundqvist et al., 1987; Merner et al., 2008). Moreover, frequent and competitive exercise increases the risk of malignant arrhythmias, heart failure and sudden death in ACM gene-mutation carriers (Corrado et al., 1990).

Lifestyle modifications, anti-arrhythmic drugs, implantable cardioverter defibrillator (ICD; Box 1) and eventually heart transplantation are the currently available therapeutic options for treating ACM. However, to date, a therapy that can tackle the cause of this disease is not available.

ACM is a relatively newly recognized disease, having only being described in 1977 as a distinct clinical entity (Fontaine et al., 1977). Since then, significant advances have been made in understanding its etiology and pathogenesis, and in diagnosing and managing the disease. Nevertheless, several biological and clinical features of ACM remain to be elucidated. Here, we review what is currently known about the etiology of ACM and its molecular mechanisms, focusing on in vitro models that are helping researchers unravel the pathology of this disease and to test hypotheses concerning its etiology and treatment. To date, a systematic review of ACM cell models, their strengths and limitations, and the insights into disease pathogenesis that they have provided, was lacking. For in vivo model reappraisal, we refer the reader to earlier reviews (McCaeley and Wehrens, 2009; Lodder and Rizzo, 2012; Pilichou et al., 2011).

ACM etiopathogenesis: the theories
The origin of ACM is still largely unknown, but different theories have been advanced to explain its etiology. In the disontogenic hypothesis, now abandoned, ACM was believed to be a congenital defect that arose from abnormal embryonic development of the RV. This explains why Fontaine and colleagues called the disease arrhythmogenic right ventricular dysplasia (ARVD) (Fontaine et al., 1977). Actually, the developmental problems are typical of Uhl’s
Therefore, the term replacement is not present in Uhl symptoms from adolescence. Moreover, myocardial fibro-adipose neonatal or infant life, whereas ACM patients typically manifest (Bowles et al., 2002). Further studies are needed to unravel the cardiomyocyte death or as a primary infective/immune mechanism. Is not clear whether the inflammation occurs as a consequence of the inflammatory cells found in the myocardium of ACM patients. It forms (Saguner et al., 2014), the name has been updated to parietal wall of the RV and which has, in the past, been confused disease, a condition characterized by the complete absence of the heart. Specifically, in ACM the main features are fibrous and fatty deposits in the ventricular myocardium, with thinning of the free walls and segmental or diffuse atrophy. Palpitation: perception of rapid and/or irregular heartbeats. Second heart field: area of multipotent progenitor cells contributing to myocardium formation during heart development. Sudden cardiac death: unexpected natural death owing to cardiac arrest, heralded by abrupt loss of consciousness within 1 hour of the onset of acute symptoms. Syncope: partial or complete loss of consciousness due to a temporary reduction in blood flow and shortage of oxygen to the brain. Ventricular arrhythmias: abnormal rapid heart rhythms originating from the ventricles. Wall motion abnormalities: abnormal motion of a region of the heart muscle, causing heart dysfunction. It can be reduced (hypokinesia), absent (akinesia) or increased (hyperkinesia). Wnt pathway: signaling pathway involved in various cellular process, such as adhesion, self-renewal, differentiation, migration and proliferation. Wnt proteins are glycoproteins that act as ligands of Frizzled receptors. The active pathway is characterized by the inhibition of glycogen synthase kinase 3, β-catenin, activating adipogenesis, fibrosis and apoptosis.

The cardiomyocyte transdifferentiation hypothesis was advanced to give an explanation of the phenomenon of myocardial substitution with fibro-fatty deposits (d’Amati et al., 2000). It is based on the supposition that the cardiomyocytes in ACM hearts could reprogram and differentiate into adipocytes as a consequence of the genetic defect. However, it is challenged today because of the limited evidence of the de-differentiation capabilities of adult cardiomyocytes.

The dystrophic theory of ACM origin currently prevails because of the significant similarities of ACM with skeletal muscular dystrophies (Basso et al., 1996). According to this hypothesis, the fibro-fatty deposits in ACM myocardium are considered to be scar tissue that replaces dead cardiomyocytes. In line with this, ACM mutations cause both cardiomyocyte death, leading to loss of myocardial tissue, and a signal for aberrant repair (Basso et al., 2012), as described further below.

Molecular mechanisms of ACM pathogenesis
Much basic and translational research activity has been devoted to understanding the mechanisms that underpin ACM pathogenesis...
Fig. 1. Pathogenic cardiac changes in ACM. (A,B) Representative images of key phenotypic features in human ACM. (A) Hematoxylin–eosin staining of the right ventricle (RV) in an ACM patient’s heart shows fat deposits (white areas) and disarrayed cardiomyocyte architecture with fibro-fatty infiltrations (asterisk). (B) An electrocardiogram trace (12 leads, listed on the left-hand side, representing the electrical activity from electrodes on the body surface) of a typical RV arrhythmia, which commonly occurs in ACM patients. (C–E) Representative light microscopy images of ACM in vitro models and studies of fat accumulation and arrhythmias. (C) Oil Red O staining of isolated cardiac mesenchymal stromal cells (C-MSCs) from an ACM patient and control highlights the typical lipid accumulation seen in ACM. Lipid accumulation is measured by evaluation of red areas into the cell lipid droplets. (D) Depiction of murine HL-1 cells, which can be used to generate in vitro models for electrophysiological studies of the sodium channel Nav1.5 in ACM. (E) The main graph depicts, on the y-axis, the average peak of sodium current ($I_{Na}$) density [measured in picoamperes/picofarad (pA/pF)] and, on the x-axis, voltage max [$V_{m}$; measured in millivolt (mV)] in wild-type (WT) HL-1 cells (black trace), HL1 cells treated with PKP2-silencing construct (PKP2-KD; red trace) and HL-1 cells treated with a non-silencing construct (PKP2-φKD; blue trace). The corresponding dot plot, in the inset, shows that silencing PKP2 in HL-1 cells (PKP2-KD) leads to a statistically significant (**$P<0.005$) decrease in sodium current density ($I_{Na}$) (see main text for a discussion of the effect of PKP2 loss on sodium current). Adapted with permission from Cerrone et al., 2014. This image (E) is not published under the terms of the CC-BY licence of this article. Promotional and commercial use of the material in print, digital or mobile device format is prohibited without permission from the publisher Wolters Kluwer. Please contact healthpermissions@wolterskluwer.com for further information. Scale bars: 100 μm.
This research has focused in particular on downstream alterations provoked by causative gene defects. Mutations in the ACM-associated genes that encode desmosomal proteins cause cardiomyocyte connections to be abnormal in shape and composition, and they also cause altered signaling in all the cell types that express the mutated genes (Al-Jassar et al., 2011; Grossmann et al., 2004; Pieperhoff et al., 2008; Bass-Zubek et al., 2009). Importantly, canonical Wnt and Hippo pathways (Box 1) have been recognized to be affected by these desmosomal mutations (Chen et al., 2014).

The Wnt pathway participates in the developmental process during embryogenesis and is implicated in adult tissue homeostasis. In the presence of an active canonical Wnt pathway, β-catenin degradation is inhibited; thus, this protein accumulates in the cytoplasm, translocates into the nucleus and interacts with T-cell factor/lymphoid enhancer factor (TCF/LEF) transcription factors, inducing proliferation and cell fate specification, including cardiomyocyte differentiation (Li et al., 2011). In ACM, the altered metabolism of plakoglobin (PG), a desmosome protein that has a high degree of homology with β-catenin, is thought to be central to disease pathogenesis. In patients with the disease, PG is abnormally found in the nuclear compartment (García-Gras et al., 2006; Sommariva et al., 2016), where it is thought to compete with β-catenin, exerting a detrimental effect on Wnt signaling and ultimately activating adipogenesis, fibrosis and apoptosis (García-Gras et al., 2006).

The Hippo pathway, which responds to cell polarity, diffusible sensing signals and mechanosensing, and which functions to regulate cell proliferation, apoptosis and cell fate, has been also linked to ACM. Yes-associated protein (YAP), the Hippo pathway effector, is phosphorylated in ACM by the Hippo kinase signaling cascade; this phosphorylation inhibits YAP canonical transcriptional activity and consequently limits cellular proliferation. Moreover, YAP interaction with β-catenin further prevents nuclear localization of the latter, inhibiting Wnt and increasing adipogenesis (Chen et al., 2014).

A primarily electrical pathogenic mechanism for ACM has also been proposed. A link between PKP2 and the gap-junction protein connexin 43 (Cx43; encoded by the gene GJA1) has been demonstrated (Oxford et al., 2007) based on their coexistence in the same macromolecular complex. This interaction network (“connexome”) was extended in 2014 to include the voltage-gated sodium channel Nav1.5 (Agullo-Pascual et al., 2014a). The electric current passing through this channel is reduced in cardiac myocytes lacking PKP2 (Sato et al., 2009). The localization of Nav1.5 to cell membranes is Cx43-dependent (Agullo-Pascual et al., 2014b); thus, functionally, Cx43 reduction parallels with Nav1.5 reduction (Jansen et al., 2012; Cerrone and Delmar, 2014). Moreover, the loss of PKP2 stimulates Cx43 complex remodeling, which results in altered intercalated disc (Box 1) structures (Oxford et al., 2007). The loss of PKP2 has been associated with Nav1.5 reduced functionality, both in PKP2 heterozygous knockout mice (Cerrone et al., 2012) and in Brugada syndrome patients (Box 1), who carry a PKP2 mutation (Cerrone et al., 2014). Interestingly, the implication of the sodium channel in ACM pathogenesis links Brugada syndrome with ACM; these disorders are already known to share some clinical features, such as RV arrhythmias and sudden death. Of note, a minor structural and functional impairment of the RV, mainly in the RV outflow tract, might also occur in Brugada patients (Pérez Riera et al., 2005; Böhm et al., 2007).

ACM-related mutations are also found in the gene encoding RYR2, a calcium release channel (Tiso et al., 2001), and in the PLN...
gene, which encodes for a membrane protein that regulates the Ca^{2+} pump in cardiac muscle cells (van der Zwaag et al., 2012). This implies that deficient excitation–contraction coupling (Box 1) might contribute to ACM. It has been hypothesized that modifications of intracellular calcium homeostasis contribute to the pathogenesis of ACM by inducing cellular injury, triggering both apoptosis and electrical instability (van der Zwaag et al., 2012; Tiso et al., 2001).

ACM associated with mutation of TMEM43, a transmembrane protein, seems to be mechanistically similar to desmosome-linked ACM, because TMEM43 mutations lead to PG redistribution, altered Cx43 phosphorylation and function, and impaired conduction velocity (Merner et al., 2008; Siragam et al., 2014). Similar observations have been made by analyzing the effect of DES mutations; DES encodes desmin, an intermediate filament protein that interacts with DSP. These mutations affect the localization of DSP and PKP2 at the intercalated discs (Otten et al., 2010). Of note, mutations in the CTNNA3 gene (van Hengel et al., 2013), which encodes for the area composita (Box 1) protein αT-catenin, are thought to alter the homodimeric interactions of the protein or its interactions with β-catenin. These data, together with the newest finding of mutations in the CDH2 gene (Turkowski et al., 2017), coding for N-cadherin, suggest that ACM could be reconsidered to be a disease affecting the area composita rather than a purely desmosomal disease.

The association of ACM with mutations of TGFβ3 has been reported (Beffagna et al., 2005). Although a direct causative role has not been proven, this association could consolidate the link between ACM and fibrosis. TGFβ3 encodes for a cytokine that stimulates fibrosis by promoting the expression of extracellular matrix genes and by modulating cell adhesion and the expression of desmosomal genes in different cell types (Kapoun et al., 2004; Yoshida et al., 1992).

Finally, ACM has been linked to mutations in genes coding for the structural proteins titin (stabilizes the sarcomere) and lamin A/C (provides a nuclear-envelope framework and interacts with chromatin), although overlap syndromes cannot be excluded. These mutations lead to an impaired cellular structural stability and a higher protein turnover (Taylor et al., 2011; Forleo et al., 2015), provoking cell death and myocardial remodeling (Box 1). Different in vitro models have helped to define the ACM cellular phenotype and to investigate these disease mechanisms.

Overview of cellular models of ACM
In this section and in Fig. 2 and Table 1, we give an overview of the in vitro models of ACM studied to date. These cell models have contributed to the current understanding of the ACM pathogenic mechanisms explained above. In vitro models investigated so far have been derived from the cardiac contractile compartment, progenitor cells, the stromal compartment and non-cardiac cells.

Cardiomyocytes
Intercalated discs are intercellular specialized areas at the end of cardiomyocytes that enable cardiac muscles to contract in a synchronized manner. They are composed of different kinds of junctions that are essential for myocardial mechanical continuity (via desmosomes), electrical coupling (via gap junctions) and electrical activity (via voltage-gated ion channels) between adjacent cells and, hence, for maintaining correct heart function. In light of the important functions of intercalated discs, cardiomyocytes have been proposed to be the pivotal cellular model in ACM. Adult human cardiomyocytes are, however, difficult to obtain and to maintain in culture; therefore, various surrogates have been used, as we describe below.

HL-1 cell line
The HL-1 cell line was obtained with the immortalization of AT-1 atrial cardiomyocytes, isolated from transgenic mice in which expression of the SV40 large T antigen was controlled by the atrial natriuretic factor promoter (Field, 1988). This line was the first cellular model introduced to mimic cardiomyocyte performance in ACM. HL-1 cells contract even after serial passaging, and retain differentiated cardiac morphological, biochemical and electrophysiological properties (Claycomb et al., 1998).

By silencing DSP through stable transfection, using siRNA in HL-1 cells, Garcia-Gras et al. demonstrated, for the first time, the translocation of PG into the nucleus, the suppression of the canonical Wnt pathway and an increase in the adipogenic gene expression with a consequent accumulation of lipid droplets (Garcia-Gras et al., 2006). This led to the hypothesis that desmosomal gene knockdown (e.g. DSP) might provoke Wnt signaling impairment, possibly mediated by PG. By knocking down PKP2 in HL-1 cells, Hippo pathway dysregulation was revealed both at the transcript and protein levels, indicating Hippo pathway involvement in ACM pathogenesis (Chen et al., 2014).

The impairment of gap junctions and its effect on electrical synchrony has been demonstrated with the use of PKP2-deficient HL-1 myocytes. Consistent with this, Cx43 membrane localization and expression is impaired in these cells (Fidler et al., 2009). A reduced current amplitude of the Nav1.5 sodium channel has also been reported in PKP2-deficient HL-1 cells (Cerrone et al., 2014). Wang et al. (2015) recently demonstrated that an increased activity of RhoA can influence Cx43 expression in ACM, providing a potential mechanism to link PKP2 deficiency to Cx43 remodeling. In addition to PKP2, DSP has also been shown to play an important role in the stability and signaling of the connexome (Zhang et al., 2013). Overall, these findings tell us that mutations in different desmosomal genes result in common impairment of electrical continuity, supporting the theory that this is a direct cause of arrhythmias in ACM.

Studies in HL-1 cells have also helped to link non-desmosomal gene mutations to arrhythmias. A TMEM43 mutation was found to cause a redistribution of junctional PG and αT-catenin, Cx43 phosphorylation, and altered conduction velocity (Siragam et al., 2014). Another study provided support for the important role of RYR2. Specifically, George et al. (2003) transfected HL-1 cardiomyocytes with a RYR2 mutated plasmid and reported higher levels of calcium release after stimulation; this affected both the contractile behavior of these cells – possibly leading to the ACM phenotype of cardiac failure – and the cellular repolarization level, thus contributing to the arrhythmic phenotype.

The impact of newly discovered ACM-linked mutations has also been studied in HL-1 cardiomyocytes through the overexpression of the mutated genes. For example, DSC2 mutations have been studied to define their pathogenicity and evaluate their effect on localization of the mutated protein (Beffagna et al., 2007; De Bortoli et al., 2010; Gehmlich et al., 2011). A PKP2 missense mutation was shown to generate an unstable PKP2 protein that was incapable of interacting with DSP and was degraded (Kirchner et al., 2012). DSG2 mutations resulted in a reduced strength of cell–cell contact, demonstrating that DSG2 is crucial for cardiomyocyte cohesion (Schlipp et al., 2014). LMNA mutations in HL-1 cells lead to altered nuclear shape and pore organization, which decrease cardiomyocyte adaptation to mechanical stress (Forleo et al., 2015). Interestingly, a role for the inhibitor of apoptosis-stimulating protein of p53 (iASPP) in maintaining the integrity of desmosomes through its interaction with DSP and DES has been modeled in HL-1 cells (Notari et al., 2014).
Cardiomyocytes from PG-knockout mice, studied in parallel with those from a double PG/β-catenin knockout, revealed that both of these N-cadherin binding partners are essential for maintaining intercalated disc structure and for mechano-electrical coupling (Swope et al., 2012). Electrophysiological studies have been performed in cardiomyocytes from PKP2 (Cerrone et al., 2012) and DSP (Gomes et al., 2012) heterozygous knockout mice, and reported a deficit or unaltered sodium current density (Box 1), respectively. Although the results with PKP2 heterozygous knockout mice are in agreement with those obtained in HL-1 cells, the sodium current in DSP-knockout murine cardiomyocytes did not show the same impairment as seen in DSP-knockdown HL-1 cells.

Transgenic zebrafish models of ACM have also been used to isolate cardiomyocytes for in vitro studies. Notably, a transgenic zebrafish with cardiac-specific expression of mutated PG has been used for mechanistic studies, revealing that correct trafficking of intercalated disc proteins is crucial for cardiomyocyte integrity (Asimaki et al., 2014; Macrae, 2010).

Even if animal-derived cardiomyocytes represent a valuable and accessible source of functional cells, they suffer the limitation of their non-human origin. Consequently, insights obtained with these tools still need to be confirmed in human-derived models.

Cardiomyocytes from induced pluripotent stem cells

Human induced pluripotent stem cells (hiPSCs) represent a tool to obtain human-derived cardiomyocytes (Brandão et al., 2017) and so overcome the interspecies issues noted above. The first hiPSC-derived ACM cardiomyocytes were generated in 2013 using skin fibroblasts from an ACM patient. These cells showed reduced PKP2 and PG expression and an increased lipid-droplet accumulation when cultured in adipogenic differentiation medium (Ma et al., 2013).
Table 1. Cell-based studies of specific aspects of arrhythmogenic cardiomyopathy

<table>
<thead>
<tr>
<th>Aspect of ACM studied</th>
<th>Cell model</th>
<th>References</th>
<th>Major findings and consistency across cell-based studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipid accumulation</td>
<td>HL-1</td>
<td>Garcia-Gras et al., 2006</td>
<td>First to link DSP silencing to lipid accumulation</td>
</tr>
<tr>
<td></td>
<td>Epicardial cells</td>
<td>Mathers et al., 2011</td>
<td>PKP2 silencing increases lipogenesis</td>
</tr>
<tr>
<td></td>
<td>c-kit⁻/Sca1⁺ cells</td>
<td>Lombardi et al., 2011</td>
<td>JUP mutation leads to lipid accumulation</td>
</tr>
<tr>
<td></td>
<td>Cardiomyocytes from hiPSCs</td>
<td>Ma et al., 2013; Caspi et al., 2013</td>
<td>PKP2 mutation leads to lipid accumulation (consistent with epicardial cell studies)</td>
</tr>
<tr>
<td></td>
<td>C-MSCs</td>
<td>Sommariva et al., 2016</td>
<td>The source of adipocytes in ACM are C-MSCs</td>
</tr>
<tr>
<td></td>
<td>FAPs</td>
<td>Lombardi et al., 2016</td>
<td>DSP silencing leads to lipid accumulation (consistent with HL-1 studies)</td>
</tr>
<tr>
<td>Wnt pathway</td>
<td>HL-1</td>
<td>Garcia-Gras et al., 2006</td>
<td>DSP silencing provokes the suppression of the canonical Wnt pathway</td>
</tr>
<tr>
<td></td>
<td>c-kit⁻/Sca1⁺ cells</td>
<td>Lombardi et al., 2011</td>
<td>JUP mutation provokes the suppression of the canonical Wnt pathway (consistent with HL-1 studies). Phenotypic amelioration through pharmacological reactivation of Wnt (BIO)</td>
</tr>
<tr>
<td></td>
<td>BMCs</td>
<td>Asimaki et al., 2016</td>
<td>Phenotypic amelioration through pharmacological reactivation of Wnt (SB216763; consistent with c-kit⁻/Sca1⁺ cell studies)</td>
</tr>
<tr>
<td></td>
<td>C-MSCs</td>
<td>Sommariva et al., 2016</td>
<td>Desmosomal mutations provoke the suppression of the canonical Wnt pathway (consistent with HL-1 and c-kit⁻/Sca1⁺ cell studies). Phenotypic amelioration through pharmacological reactivation of Wnt (BIO; consistent with c-kit⁻/Sca1⁺ cell and BMC studies)</td>
</tr>
<tr>
<td></td>
<td>FAPs</td>
<td>Lombardi et al., 2016</td>
<td>Desmosomal mutations provoke the suppression of the canonical Wnt pathway (consistent with HL-1, c-kit⁻/Sca1⁺ cell and C-MSC studies). Phenotypic amelioration through pharmacological reactivation of Wnt (BIO; consistent with c-kit⁻/Sca1⁺ cell, BMC and C-MSC studies)</td>
</tr>
<tr>
<td>Hippo pathway</td>
<td>HL-1</td>
<td>Chen et al., 2014</td>
<td>Dysregulation of Hippo pathway</td>
</tr>
<tr>
<td></td>
<td>Cardiomyocytes from animal models</td>
<td>Oxford et al., 2007</td>
<td>PKP2 silencing provokes decreased Cx43 expression and abnormal localization</td>
</tr>
<tr>
<td></td>
<td>Epicardial cells</td>
<td>Oxford et al., 2007</td>
<td>PKP2 silencing provokes decreased Cx43 expression and abnormal localization (consistent with studies in cardiomyocytes from animal models)</td>
</tr>
<tr>
<td></td>
<td>HL-1</td>
<td>Fidler et al., 2009</td>
<td>PKP2 silencing provokes decreased Cx43 expression and abnormal localization (consistent with studies in cardiomyocytes from animal models and in epicardial cells)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Zhang et al., 2013</td>
<td>DSP silencing provokes decreased Cx43 expression and abnormal localization (consistent with studies in cardiomyocytes from animal models and in epicardial cells)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wang et al., 2015</td>
<td>Increased RhoA activity is linked to Cx43 remodeling</td>
</tr>
<tr>
<td>Nav1.5 channel</td>
<td>Cardiomyocytes from animal models</td>
<td>Sato et al., 2009; Cerrone et al., 2012</td>
<td>PKP2 deficiency reduces Nav1.5 current amplitude</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gomes et al., 2012; Zhang et al., 2013</td>
<td>DSP deficiency does not alter Nav1.5 current density (differs from HL-1 studies)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cerrone et al., 2014</td>
<td>PKP2 deficiency reduces Nav1.5 current amplitude [consistent with Sato et al. (2009) study and not with Gomes et al. (2012)]</td>
</tr>
<tr>
<td>Validation of mutations</td>
<td>HL-1</td>
<td>George et al., 2003</td>
<td>Insight into RYR2 mutation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Belfagna et al., 2007</td>
<td>Insight into DSC2 mutation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kirchner et al., 2012</td>
<td>Insight into PKP2 mutation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>van Hengel et al., 2013</td>
<td>Insight into CTNNA3 mutation (area composita involvement)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Schlipp et al., 2014</td>
<td>Insight into TMEM43 mutation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Siragam et al., 2014</td>
<td>Insight into DSG2 mutation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Forleo et al., 2015</td>
<td>Insight into LMNA mutation</td>
</tr>
<tr>
<td></td>
<td>Cardiomyocytes from animal models</td>
<td>Belfagna et al., 2007</td>
<td>Insight into DSC2 mutation</td>
</tr>
<tr>
<td></td>
<td>HEK293T cells</td>
<td>van Hengel et al., 2013</td>
<td>Insight into CTNNA3 mutation (area composita involvement)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Koop et al., 2008</td>
<td>Insight into RYR2 mutation</td>
</tr>
<tr>
<td></td>
<td>COS cells</td>
<td>van Hengel et al., 2013</td>
<td>Insight into CTNNA3 mutation (area composita involvement)</td>
</tr>
<tr>
<td></td>
<td>Keratinocytes</td>
<td>Gehmlich et al., 2011</td>
<td>Insight into DSC2 mutation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rasmussen et al., 2014</td>
<td>Insight into PKP2 and DSG2 mutations</td>
</tr>
</tbody>
</table>

BIO, 6-bromoindirubin-3’-oxime; BMCs, buccal mucosa cells; C-MSCs, cardiac mesenchymal stromal cells; CTNNA3, α-catenin; Cx43, connexin 43; DSC2, desmocollin 2; DSG2, desmoglein 2; DSP, desmoplakin; FAPs, fibro-adipocyte progenitors; hiPSCs, human induced pluripotent stem cells; JUP, plakoglobin; LMNA, lamin A/C; PKP2, plakophilin 2; RYR2, ryanodine receptor 2; TMEM43, transmembrane protein 43.

One of the unsolved shortcomings of hiPSC-derived cardiomyocytes is their fetal-like phenotype (Ma et al., 2013), which does not fully recapitulate the adult cardiomyocyte. Kim et al. (2013) partially overcame this issue by inducing an adult-like metabolism in ACM-hiPSC cardiomyocytes by stimulating fatty-acid oxidation. Subsequently, desmosomal ultrastructural changes were studied in cardiomyocytes differentiated from ACM-hiPSCs, identifying a correlation between the extent of desmosomal structural abnormalities and predisposition to lipid accumulation (Caspi et al., 2013).
Despite well-known technical limitations, including a high variability among clones obtained from the same donor, the advantages of hiPSCs as ACM cell models include their human origin, their potential unlimited availability and their suitability for high-throughput screening. Moreover, they carry patient genomes, representing a unique tool for personalized-medicine approaches. It is also worth noting that, to date, no studies have attempted to use genome editing to correct ACM-associated mutations in ACM-hiPSCs, which would provide indisputable proof of phenotype–genotype coupling.

**Progenitor cells**

Progenitor cells have been used to model ACM because of their stem-cell-like multipotency, and their higher adipogenic potential compared to terminally differentiated cells.

**c-kit+/Sca1+ murine cells**

**c-kit+/Sca1+ murine cells** have been used as an ACM cell model. c-kit+ cells are the first resident stem-cell population identified in the heart (Beltrami et al., 2003). These cells are self-renewing and multipotent in vitro, and can repair damaged myocardium (Dey et al., 2013). They can also accumulate fat upon in vitro adipogenic stimulation (Gambini et al., 2010). Sca1 identifies a heterogeneous population of adult cells, including endothelial, stromal and vascular cell progenitors. Cells expressing Sca1 show typical features of stem cells, are characterized by cardiogenic potentials (Oh et al., 2003) and can accumulate fat in vitro (Matsuura et al., 2004). JUP-overexpressing c-kit+/Sca1+ cells have been obtained from transgenic mouse hearts and used to show that PG translocation into the nucleus and the consequent repression of Wnt/β-catenin lead to adipogenic differentiation (Lombardi et al., 2011). This study, in accordance with previous findings, helped to demonstrate that PG is an essential mediator of the myogenesis-to-adipogenesis switch, and that adipocytes in ACM patients’ hearts originate, at least in part, from c-kit+/Sca1+ cells (Lombardi et al., 2011). However, this last finding has been questioned by a recent study that provided evidence of few c-kit+ cells differentiating in adipocytes in ACM hearts (Sommariva et al., 2016). Lately, even the cardiomyogenic potential of c-kit+ cells is a matter of debate (van Berlo et al., 2014).

A key shortcoming of these progenitors is that they are difficult to obtain by cell sorting, and they represent a very small subpopulation of cardiac cells. It is also questionable whether they are all resident cells. Finally, the c-kit+/Sca1+ cells extensively studied were of mouse origin.

**Epicardial cells**

Epicardial cells compose the epithelial monolayer surrounding the heart. They exert both a protective role and a functional role in the myocardial response to injury. Epicardial cells share a common origin with second heart field (Box 1) progenitors (Zhou et al., 2008), and have been used to model ACM. The silencing of PKP2 in epicardial progenitors from WT neonatal rat hearts causes changes in Cx43 amount and distribution (Oxford et al., 2007). In line with other data, PKP2 and Cx43 coexist in the same macromolecular complex in epicardial cells (Oxford et al., 2007). Subsequently, the role of PKP2 in the migration, proliferation and transdifferentiation of cultured primary epicardial cells was studied, and demonstrated that increased lipogenesis and myofibroblast differentiation could be related to PKP2 loss. Therefore, it was theorized that epicardial and epicardial-derived cells can act as adipocyte progenitors and contribute to fibrosis (Matthes et al., 2011). Further studies are needed to provide robust proof of this hypothesis.

Fibro-adipocyte progenitors

Fibro-adipocyte progenitors (FAPs) represent an alternative cellular source for investigating fat and fibrosis accumulation in ACM (Lombardi et al., 2016). FAPs are resident skeletal-muscle progenitor cells, characterized by the platelet-derived growth factor receptor α (PDGFRα) marker. FAPs seem to be bi-potential: different subpopulations express fibroblast markers or adipogenic transcription factors. Using this model, Lombardi et al. (2016) confirmed that DSP deficiency suppresses Wnt signaling, and that this effect is ameliorated through Wnt pharmacological reactivation. Moreover, adipocyte proliferation was excluded in ACM, in favor of the hypothesis of FAP differentiation through the activation of adipogenic transcription factors.

**Non-cardiac cells**

**Buccal mucosa cells**

Buccal mucosa cells Owing to the limited availability of human myocardial samples, Asimaki et al. (2016) have proposed buccal mucosa cells (BMCs) as an in vitro model of ACM. BMCs, which are obtained easily from the inside of the mouth, are epithelial cells; thus, they express gap junctions and desmosomes, like cardiac cells. The authors studied the distribution of proteins usually present in intercalated discs (e.g. PG and Cx43) and found the same altered distribution in ACM-patient-derived BMCs as in the patient cardiac tissue. They also showed that Wnt pharmacological reactivation can apparently restore normal PG and Cx43 localization in ACM cells (Asimaki et al., 2016). Thus, despite their non-cardiac derivation, these cells might be an additional useful tool that can be easily obtained from large numbers of ACM patients at minimal cost to investigate disease mechanisms and use in drug screening.

**Primary keratinocytes**

Primary keratinocytes are another easily obtainable adult human-derived cell type that express high levels of all isoforms of desmosomal proteins (Gerull, 2014). Rasmussen et al. (2014) showed that changes in myocardial expression of PKP2 and DSG2 are mirrored by similar changes in keratinocytes (Rasmussen et al., 2014). These findings suggest that, despite being of non-cardiac origin, these keratinocytes might represent a new accessible source of cells to model patient-specific ACM mutations.

**HEK293T cells**

The HEK293T cell line, originally derived from human embryonic kidney, has been used to conduct functional tests on a newly identified ACM-associated genetic mutation in CTNN43. Transfection of the mutant gene into this cell line revealed that the interaction between mutant αT-catenin and β-catenin was weaker than with WT αT-catenin (van Hengel et al., 2013). This cell model, which naturally lacks endogenous RYR2 channels, has also been used to study the effect of two RYR2 mutations on the store-overload-induced calcium-release activity. This study found that the combination of the two RYR2 mutations, which affect important residues for RYR2 tetramer formation and function, caused significant changes in calcium release activity (Koop et al., 2008). By identifying the additive effect of the two mutations, this study revealed the reason why carriers of compound heterozygous mutations in the RYR2 gene can be affected by ACM.

**COS cells**

COS cells, immortalized cell lines derived from monkey kidney tissue, have also been used to investigate functional impairments caused by ACM-associated mutations. Rajkumar et al. (2012) used
et al., 2011), and so cell-based models are preferable to investigate causing ACM. An impaired maturation of mutated DSC2 was observed, along with a reduced binding to PG (Gehmliech et al., 2011). This finding is in accordance with the reduced localization of PG at desmosomes in intercalated discs of ACM patients’ heart tissue, reported earlier by the same authors (Asimaki et al., 2009). This model, however, suffers different limitations: not only are these cells not cardiac, but they are also of animal origin.

Adult cardiac stromal cells
In 2015, we proposed non-contractile cardiac mesenchymal stromal cells (C-MSCs) as a novel cell model for ACM (Sommariva et al., 2016). These cells are abundant in the heart and are involved in maintaining cardiac cell structure and functional homeostasis in physiological and pathological conditions (Brown et al., 2005). In 2010, C-MSCs were isolated from human adult auricles (Box 1) and characterized for the first time (Rossini et al., 2010). C-MSCs are primary cells obtained directly from human cardiac tissue after enzymatic digestion with collagenase and selection for plastic adherence, and they express typical mesenchymal markers (CD29, CD105, CD44, CD90) (Rossini et al., 2010). Like their bone-marrow counterpart (BM-MSCs), C-MSCs can differentiate in endothelium, osteocytes and adipocytes (Rossini et al., 2010), and are more likely than BM-MSCs to express cardiovascular lineage markers upon cardiogenic stimulus. They can also be easily amplified and maintained in vitro for many passages. Notably, C-MSCs carry patient-specific mutations and their genetic background (Sommariva et al., 2016). We demonstrated, for the first time, that, in the explanted hearts of ACM patients, C-MSCs are involved in active adipogenic differentiation (Sommariva et al., 2016). C-MSCs isolated from patient ventricular biopsies express desmosomal genes and, when cultured in adipogenic medium, are more prone to differentiate into adipocytes than are control C-MSCs (Sommariva et al., 2016). We took advantage of this cell model to confirm some of the above-mentioned molecular mechanisms of ACM, such as PG nuclear localization. Moreover, C-MSCs were used to demonstrate that ACM-specific features are dependent on PKP2 deficiency and on Wnt pathway mis-regulation (Sommariva et al., 2016). In conclusion, C-MSCs represent another promising new cell model for in vitro studies of ACM mechanisms.

Current cell models of ACM: pros and cons
As highlighted in the previous section, different molecular mechanisms of ACM have been investigated in vitro thanks to the availability of several cell models. Below, we aim to point out the `lights and shadows’ of each cell type, to help guide researchers who want to focus on a specific aspect of ACM. Each in vitro model described has intrinsic advantages and disadvantages, depending on its origin (animal versus human; cardiac versus non-cardiac), its maturity (embryonal or undifferentiated versus adult or fully differentiated) and on the cell type (parenchymal versus stromal). On the basis of these features, and taking together the findings summarized in Table 1 and Fig. 2, it is possible to choose which should be the most suitable cell type in which to investigate specific aspects of ACM.

ACM mouse models do not show the extensive cardiac adipose deposits typical of ACM patients (Cerrone et al., 2012; Kruschke et al., 2011), and so cell-based models are preferable to investigate causative pathways linked to lipid metabolism. Adult cells of human cardiac origin, carrying patient-specific mutations and genetic backgrounds, represent the best tool for these studies. However, adult cardiomyocytes are of limited accessibility and must be obtained by invasive sampling. Moreover, they do not replicate, are difficult to maintain in culture and impose the constraint of restricted transdifferentiation potential. Indeed, manifest lipid accumulation has been reported only in immature cardiomyocyte models, such as those obtained from hiPSCs, which still possess a residual potency (Kim et al., 2013). Also, progenitor cells do differentiate easily in vitro, but this could possibly be related more to their multipotency than to disease-specific differentiation (Lombardi et al., 2011; Matthes et al., 2011). To overcome these limitations, C-MSCs represent the ideal model for studying lipid metabolism, because they undergo adipogenic differentiation in patient hearts and maintain the same ability in vitro (Sommariva et al., 2016).

Because electrical activity is restricted to cardiomyocytes, these provide the only eligible models to investigate gap-junction and ion-channel localization, and for electrophysiological studies: the cardiomyocytes can be either primary or immortalized cells obtained from animal models or from patient hiPSCs. To date, limited electrophysiological data are available on the latter (Kim et al., 2013), although hiPSC-derived cardiomyocytes are potentially the best model to recapitulate the human pathological scenario, with the limitation of a fetal-like phenotype (meaning that adult-onset disease cannot be mimicked). Moreover, further studies on hiPSC-derived cardiomyocytes could help to shed further light on different currents, including sodium current, which have been studied in murine-derived cell models, with conflicting results (Gomes et al., 2012; Zhang et al., 2013).

Despite their non-cardiac derivation, BMCs represent a possible tool for large population studies because the sampling technique is not invasive. Other non-cardiac (and easily accessible) cells in which desmosomes are expressed could eventually be considered in the future.

Finally, functional validation of mutations often relies on overexpression of plasmids carrying mutated genes. Undoubtedly, it is preferable to use patient-derived cells that already carry the desired mutations, such as primary cells or hiPSC-derived cardiomyocytes. However, the presence of the patient’s whole genetic background, including main mutations and modifier variants, might make it difficult to assign single-variant pathogenicity. To overcome this issue and to enable a direct comparison between mutated and WT cells, the more controlled tool of cardiomyocytes from transgenic animals have been used (Beffigna et al., 2007; van Hengel et al., 2013). The newest biomolecular techniques, such as CRISPR/Cas9 will now allow direct correction of mutations in human cells, thus allowing direct comparison between mutated and corrected cells.

Unanswered questions and future perspectives
Despite the advances made to date, many questions about ACM pathogenesis remain unanswered, and cell models could help to shed light on these outstanding questions.

First, the genetic causes of ACM are not yet fully known. Notably, about 50% of the probands undergoing genetic screening fail to have a causative mutation in ACM-associated genes (Marcus et al., 2013). ACM is characterized by high phenotypic variability and low penetrance, and, in some patients, by compound heterozygosity (Lazzarini et al., 2015). Moreover, a screening of ACM-associated genetic variants in a population of healthy individuals resulted in 18% positivity rate, questioning the causative role of these variants (Andreasen et al., 2013). This
evidence indicates that considerable genetic heterogeneity is involved in ACM and that it might not be a monogenic Mendelian disorder. Moreover, non-genetic cofactors might also contribute to ACM pathogenesis, either providing the trigger for disease development or worsening disease severity. A deeper understanding of ACM-associated genes and cofactors might help to unravel the contribution of new pathways, or to refine our understanding of other known molecular mechanisms. Direct comparisons of desmosomal versus non-desmosomal gene-associated mutations are needed in the same cell type to better understand downstream disease mechanisms. Given the complexity of ACM genetics, the identification of digenic inheritance (Xu et al., 2010) and the contribution of modifier alleles (Sen-Chowdhry et al., 2010), it would be interesting to investigate cell models modified with more than one ACM-associated mutation. Alternatively, primary cells, carrying the entire genetic background of an ACM patient, could be compared with controls in which the disease variant is selectively corrected. These cells will help to unravel the specific contribution of what is considered the main causative mutation, with respect to the pathogenicity of the other variants. Interestingly, potential mosaicism or somatic mutations (Lubitz and Ellinor, 2015) have never been investigated in ACM. Human cardiac primary cells are suitable for this.  

Certain ACM features are difficult to recapitulate in vitro. Specific studies are needed to understand the causes of adult-onset ACM and male prevalence. In long QT (Box 1) (Salama and Bett, 2014) and Brugada (Benito and Berruezo, 2014) syndromes, the steroid profile is thought to provoke post-puberty cardiac electrical-property changes. ACM gender differences deserve specific mechanistic studies using male versus female models or investigations about the effect of hormones on the ACM cellular phenotypes. In addition, the reason for the association between intense physical activity and ACM risk (Saberniak et al., 2014) is not known. It has been hypothesized that strong mechanical stretch during exercise acts on the RV, leading to myocardial damage and promoting cardiac remodeling. Furthermore, intense sport provokes sympathetic stimulation, which is a known trigger of arrhythmias (Shen and Zipes, 2014). Indeed, impairment of cardiac sympathetic innervation and a significant reduction of postsynaptic β-adrenergic density have been described in ACM patients (Wichter et al., 2000). In this context, it would be interesting to address the cellular effect of mechanical or chemical stimulation. Moreover, the preponderance of RV myocardial remodeling in ACM has not yet been fully explained. A tentative response to this question has been provided by evidence that the cellular developmental origin of pre-adipocytes in ACM hearts is the second heart field (Lombardi et al., 2009; Zhou et al., 2008), which is finely tuned through direct and paracrine interactions. New studies will help to unravel the contribution of new pathways, or to refine our understanding of ACM-associated genes and cofactors might help to create complex cellular models that allow in-depth mechanistic assessments as well as tissue-level validation of the effect of novel therapeutic compounds.

**Funding**

This work has been supported by Ricerca Corrente from Italian Ministry of Health (Ministero della Salute).

**References**


